Article
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.
Journal of the National Comprehensive Cancer Network : JNCCN - 1 Feb 2022
Greenberg Peter L, Stone Richard M, Al-Kali Aref, Bennett John M, Borate Uma, Brunner Andrew M, Chai-Ho Wanxing, Curtin Peter, de Castro Carlos M, Deeg H Joachim, DeZern Amy E, Dinner Shira, Foucar Charles, Gaensler Karin, Garcia-Manero Guillermo, Griffiths Elizabeth A, Head David, Jonas Brian A, Keel Sioban, Madanat Yazan, Maness Lori J, Mangan James, McCurdy Shannon, McMahon Christine, Patel Bhumika, Reddy Vishnu V, Sallman David A, Shallis Rory, Shami Paul J, Thota Swapna, Varshavsky-Yanovsky Asya Nina, Westervelt Peter, Hollinger Elizabeth, Shead Dorothy A, Hochstetler Cindy
Abstract excerpt
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management of patients with MDS based on a review of clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts meets on an annual basis to update the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.